UNITED STATES

                     SECURITIES AND EXCHANGE COMMISSION

                           Washington, D.C. 20549

                                  FORM 10-Q

              Quarterly Report Pursuant to Section 13 or 15(d)
                   of the Securities Exchange Act of 1934


             For the quarterly period ended August 31, 1996
                                            ---------------

                       Commission file number 0-13003
                                              -------

                                  E-Z-EM, Inc.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

                   Delaware                          11-1999504     
        -------------------------------          -------------------
        (State or other jurisdiction of           (I.R.S. Employer
        incorporation or organization)           Identification No.)


                717 Main Street, Westbury, New York         11590
--------------------------------------------------------------------------------
          (Address of principal executive offices)       (Zip Code)

      Registrant's telephone number, including area code (516) 333-8230
                                                          -------------


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.

                          Yes / X /    No /  /

On October 11, 1996,  there were 4,035,346  shares of the  registrant's  Class A
Common Stock outstanding and 5,264,632 shares of the registrant's Class B Common
Stock outstanding.



                                Page 1 of 15
                          Exhibit Index on Page 14

<PAGE>
                        E-Z-EM, Inc. and Subsidiaries

                                    INDEX

                                                                  

PART 1:  FINANCIAL INFORMATION                                    PAGE

  Item 1.  Financial Statements

    Consolidated Balance Sheets - August 31, 1996 and
      June 1, 1996                                                3 - 4

    Consolidated Statements of Earnings - thirteen weeks
      ended August 31, 1996 and September 2, 1995                   5

    Consolidated Statement of Stockholders' Equity - thirteen
      weeks ended August 31, 1996                                   6

    Consolidated Statements of Cash Flows - thirteen weeks
      ended August 31, 1996 and September 2, 1995                 7 - 8

    Notes to Consolidated Financial Statements                    9 - 10

  Item 2.  Management's Discussion and Analysis of Financial
             Condition and Results of Operations                 11 - 13

PART II:  OTHER INFORMATION

  Item 5.  Other Information                                       14

  Item 6.  Exhibits and Reports on Form 8-K                        14

                                      -2-
<PAGE>
                          E-Z-EM, Inc. and Subsidiaries

                           CONSOLIDATED BALANCE SHEETS
                                 (in thousands)


                                                  August 31,     June 1,
               ASSETS                                1996         1996 
                                                     ----         ---- 
                                                 (unaudited)    (audited)

CURRENT ASSETS
  Cash and cash equivalents                        $ 2,674      $ 3,363
  Debt and equity securities                        19,426       20,247
  Accounts receivable, principally
    trade, net                                      16,304       16,152
  Inventories                                       25,974       23,708
  Other current assets                               3,163        2,936
                                                    ------       ------
      Total current assets                          67,541       66,406

PROPERTY, PLANT AND EQUIPMENT - AT COST,
  less accumulated depreciation and
  amortization                                      21,761       21,823

COST IN EXCESS OF FAIR VALUE OF NET ASSETS
  ACQUIRED, less accumulated amortization              542          558

INTANGIBLE ASSETS, less accumulated
  amortization                                         750          767

DEBT AND EQUITY SECURITIES                           2,081        3,647

OTHER ASSETS                                         3,474        2,836
                                                   -------      -------
                                                   $96,149      $96,037
                                                   =======      =======



The accompanying notes are an integral part of these financial statements.

                                      -3-
<PAGE>
                          E-Z-EM, Inc. and Subsidiaries

                           CONSOLIDATED BALANCE SHEETS
                 (in thousands, except share and per share data)


                                                  August 31,     June 1,
     LIABILITIES AND STOCKHOLDERS' EQUITY            1996         1996
                                                    ------       ------
                                                 (unaudited)    (audited)

CURRENT LIABILITIES
  Notes payable                                    $ 1,407      $   979
  Current maturities of long-term debt                 266          268
  Accounts payable                                   5,779        5,095
  Accrued liabilities                                5,411        6,218
  Accrued income taxes                                 506          338
                                                   -------      -------
      Total current liabilities                     13,369       12,898

LONG-TERM DEBT, less current maturities                616          680

OTHER NONCURRENT LIABILITIES                         1,894        1,856

CONTINGENCIES                                       ------       ------

      Total liabilities                             15,879       15,434
                                                    ------       ------

STOCKHOLDERS' EQUITY
  Preferred stock, par value $.10 per
    share - authorized, 1,000,000 shares;
    issued, none                                        -            -
  Common stock
    Class A (voting),  par value $.10 per
      share - authorized,  6,000,000 shares;
      issued and outstanding 4,035,346 shares
      at August 31, 1996 and June 1, 1996              403          403
    Class B (nonvoting), par value $.10 per
      share - authorized,  10,000,000 shares;
      issued and outstanding  5,219,189 shares
      at August 31, 1996 and 5,199,615 shares
      at June 1, 1996                                  522          520
  Additional paid-in capital                        15,303       15,165
  Retained earnings                                 63,860       63,347
  Unrealized holding gain on debt and equity
    securities                                       1,348        2,360
  Cumulative translation adjustments                (1,166)      (1,192)
                                                    -------      -------
      Total stockholders' equity                    80,270       80,603
                                                    -------      -------
                                                   $96,149      $96,037
                                                    ======       ======





The accompanying notes are an integral part of these financial statements.

                                      -4-

<PAGE>
                          E-Z-EM, Inc. and Subsidiaries

                       CONSOLIDATED STATEMENTS OF EARNINGS
                                   (unaudited)
                 (in thousands, except share and per share data)

                                                  Thirteen weeks ended
                                                  --------------------
                                                  August 31,  September 2,
                                                     1996         1995
                                                     ----         ----

Net sales                                          $23,355      $21,999

Cost of goods sold                                  13,490       12,868
                                                    ------       ------
      Gross profit                                   9,865        9,131
                                                    ------       ------
Operating expenses
  Selling and administrative                         7,835        6,990
  Research and development                           1,523        1,317
                                                    ------       ------
    Total operating expenses                         9,358        8,307
                                                    ------       ------
      Operating profit                                 507          824

Other income (expense)
  Interest income                                      213           59
  Interest expense                                     (61)         (64)
  Other, net                                            50           51
                                                     -----        -----
      Earnings from continuing operations
        before income taxes                            709          870

Income tax provision                                   196          130
                                                     -----        -----
      Earnings from continuing operations              513          740

Discontinued operation:
  Losses from operations, net of income tax
    provision of $1 in 1995                                        (171)
                                                     -----        ------
      NET EARNINGS                                 $   513      $   569
                                                     =====        =====

Earnings from continuing operations per common share
  Primary and fully diluted                        $   .05      $   .08
                                                     =====        =====

Earnings per common share
  Primary and fully diluted                        $   .05      $   .06
                                                     =====        =====

Weighted average common shares
  Primary                                       10,071,568    9,267,075
                                                ==========    =========
  Fully diluted                                 10,071,568    9,473,659
                                                ==========    =========
The accompanying notes are an integral part of these financial statements.

                                      -5-
<PAGE>
                          E-Z-EM, Inc. and Subsidiaries

                 CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

                      Thirteen weeks ended August 31, 1996
                                   (unaudited)
                        (in thousands, except share data)


<TABLE>
<CAPTION>

                                                                                              Unrealized
                                    Class  A            Class  B                              holding gain
                                   common stock        common stock    Additional             on debt        Cumulative 
                                -----------------    ---------------   paid-in     Retained   and equity     translation
                                Shares     Amount    Shares   Amount   capital     earnings   securities     adjustments    Total
                                ------     ------    ------   ------   ----------  --------   ----------     ------------   -----
<S>                              <C>         <C>    <C>         <C>     <C>        <C>         <C>             <C>         <C>
Balance at June 1, 1996          4,035,346   $403   5,199,615   $520    $15,165    $63,347     $2,360          $(1,192)    $80,603

Exercise of stock options                              19,057      2        133                                                135
Issuance of stock                                         517                 5                                                  5
Net earnings                                                                           513                                     513
Unrealized holding loss on debt
  and equity securities                                                                        (1,012)                      (1,012)
Foreign currency translation
  adjustments                                                                                                       26          26
                                 ---------    ---   ---------    ---     ------     ------     ------            -----     -------
Balance at August 31, 1996       4,035,346   $403   5,219,189   $522    $15,303    $63,860     $1,348          $(1,166)    $80,270
                                 =========    ===   =========    ===     ======     ======     ======            =====     =======
</TABLE>




The accompanying notes are an integral part of this financial statement.

                                      -6-
<PAGE>
                          E-Z-EM, Inc. and Subsidiaries

                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (unaudited)
                                 (in thousands)


                                                     Thirteen weeks ended
                                                    -----------------------
                                                    August 31,  September 2,
                                                      1996         1995
                                                      ----         ----

Cash flows from operating activities:
  Net earnings                                      $  513       $  569
  Adjustments to reconcile net earnings
    to net cash (used in) provided by
    operating activities
      Depreciation and amortization                    690          688
      Loss on sale of investments                       27
      Minority share of subsidiary's
        operations                                                 (164)
      Deferred income taxes                              7           17
      Changes in operating assets and
        liabilities
          Accounts receivable                         (152)       1,165
          Inventories                               (2,266)        (825)
          Other current assets                        (227)         373
          Other assets                                 (97)        (273)
          Accounts payable                             684         (720)
          Accrued liabilities                         (807)        (185)
          Accrued income taxes                         161          103
          Other noncurrent liabilities                  41           40
                                                     -----        -----

            Net cash (used in) provided by
              operating activities                  (1,426)         788
                                                    -------       -----

Cash flows from investing activities:
  Additions to property, plant and
    equipment, net                                    (593)        (961)
  (Increase) decrease in debt and equity
    securities                                         807           (5)
                                                     -----        ------

      Net cash provided by (used in) investing
        activities                                     214         (966)
                                                     -----        ------

Cash flows from financing activities:
  Proceeds from issuance of debt                       750          200
  Repayments of debt                                  (377)        (313)
  Proceeds from issuance of loan by
    minority shareholder                                            231
  Proceeds from exercise of stock options              135          100
  Proceeds from issuance of stock in connection
    with the stock purchase plan                         5            2
                                                     -----        -----

      Net cash provided by financing activities        513          220
                                                     -----        -----

                                      -7-

<PAGE>
                          E-Z-EM, Inc. and Subsidiaries

                CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
                                   (unaudited)
                                 (in thousands)


                                                     Thirteen weeks ended
                                                    -----------------------
                                                    August 31,  September 2,
                                                      1996         1995
                                                      ----         ----

Effect of exchange rate changes on
  cash and cash equivalents                         $   10       $ (119)
                                                    ------       -------

      DECREASE IN CASH AND CASH
        EQUIVALENTS                                   (689)         (77)

Cash and cash equivalents
  Beginning of period                                3,363        3,962
                                                    ------       -------

  End of period                                     $2,674       $3,885
                                                     =====        =====

Supplemental disclosures of cash flow information:
    Cash paid during the period for:
        Interest                                    $   20       $   40
                                                     =====        =====
        Income taxes (net of $12 and $69
          in refunds in 1996 and 1995,
          respectively)                              $  15       $  127
                                                     =====        =====







The accompanying notes are an integral part of these financial statements.

                                      -8-
<PAGE>
                          E-Z-EM, Inc. and Subsidiaries

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                      August 31, 1996 and September 2, 1995
                                   (unaudited)


NOTE A - CONSOLIDATED FINANCIAL STATEMENTS

  The  consolidated  balance  sheet as of  August  31,  1996,  the  consolidated
    statement of stockholders'  equity for the period ended August 31, 1996, and
    the consolidated statements of earnings and cash flows for the periods ended
    August 31, 1996 and  September  2, 1995,  have been  prepared by the Company
    without audit. In the opinion of management,  all adjustments (which include
    only  normally  recurring  adjustments)  necessary  to  present  fairly  the
    financial position,  changes in stockholders' equity,  results of operations
    and cash flows at August 31, 1996 (and for all periods  presented) have been
    made.

  Certain information and footnote  disclosures,  normally included in financial
    statements   prepared  in  accordance  with  generally  accepted  accounting
    principles,  have been  condensed  or omitted.  It is  suggested  that these
    consolidated  financial statements be read in conjunction with the financial
    statements  and notes  thereto  included in the fiscal 1996 Annual Report on
    Form 10-K filed by the Company on August 30, 1996. The results of operations
    for the  periods  ended  August  31,  1996  and  September  2,  1995 are not
    necessarily  indicative of the  operating  results for the  respective  full
    years.

  The consolidated financial statements include the accounts of E-Z-EM, Inc. and
    all 100%-owned  subsidiaries,  as well as the accounts of Surgical  Dynamics
    Inc. ("SDI"), a 51%-owned subsidiary prior to its sale in November 1995 (the
    "Company").   SDI  has  been  reported  as  a  discontinued  operation  and,
    accordingly,  the Company's proportionate share of losses from operations of
    SDI have been classified as a discontinued  operation for the thirteen weeks
    ended  September  2, 1995 in the  accompanying  consolidated  statements  of
    earnings.


NOTE B - INVENTORIES

  Inventories consist of the following:

                                                  August 31,     June 1,
                                                     1996         1996
                                                    ------       ------
                                                      (in thousands)

    Finished goods                                 $14,267      $13,157
    Work in process                                  1,090        1,159
    Raw materials                                   10,617        9,392
                                                    ------       ------
                                                   $25,974      $23,708
                                                    ======       ======

                                      -9-
<PAGE>
                          E-Z-EM, Inc. and Subsidiaries

             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

                      August 31, 1996 and September 2, 1995
                                   (unaudited)


NOTE C - COMMON STOCK

  Under the 1983 and 1984 Stock  Option  Plans,  options for 19,057  shares were
    exercised at prices ranging from $4.48 to $5.72 per share, options for 2,455
    shares were cancelled at prices ranging from $4.48 to $9.10 per share and no
    options were granted during the thirteen weeks ended August 31, 1996.

  Under the Employee Stock Purchase Plan, 517 shares were purchased at $9.67 per
    share  during the  thirteen  weeks ended  August 31,  1996.  Total  proceeds
    received by the Company approximated $5,000.


NOTE D - CONTINGENCIES

  The Company is presently a defendant in a product liability action.  This suit
    claims damages based upon alleged injuries  resulting from the use of one of
    the  Company's  products.  The  action is in its early  stages and while the
    Company is actively defending against the claim, it is unable to predict its
    outcome.  It should be noted that in this  action  the  Company is one among
    several  defendants  and, as such, the Company's  liability,  if any, is not
    quantifiable  at this time.  The Company  does not believe that the ultimate
    outcome  in  this  action  will  have  a  material  adverse  effect  on  the
    consolidated financial statements.

  The  Company  has  been  sued  by  Olympia  Holding  Corporation  p/k/a  P-I-E
    Nationwide,  Inc.  for  $443,830.  The suit,  filed on October  5, 1992,  is
    presently  pending in the U.S.  Bankruptcy  Court for the Middle District of
    Florida. The Company is being represented in this action by a law firm which
    is also  representing  numerous  other  defendants  being  sued by the  same
    plaintiff  on the same  grounds -  recovery  for  alleged  undercharges  for
    freight carriage.  It is not possible,  at this stage, to determine what, if
    any,  liability  exists  with  respect to the  Company in this  matter.  The
    Company will vigorously  defend against this action; it has been informed by
    legal counsel that there exist numerous valid defenses to this case.


NOTE E - RECLASSIFICATIONS

  Certain  reclassifications have been made to the prior year amounts to conform
    to the current year presentation.


                                      -10-
<PAGE>
                          E-Z-EM, Inc. and Subsidiaries

                      MANAGEMENT'S DISCUSSION AND ANALYSIS
                OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


     The following discussion and analysis is based on the results of continuing
operations of the Company.

QUARTERS ENDED AUGUST 31, 1996 AND SEPTEMBER 2, 1995

     The  Company's  quarters  ended August 31, 1996 and  September 2, 1995 both
represent thirteen weeks.

RESULTS OF OPERATIONS

     SEGMENT OVERVIEW

     The Diagnostic products industry segment includes both contrast systems and
non-contrast  systems.  Diagnostic  product  sales,  which  decreased  5% in the
quarter,  accounted  for 80% of sales in the current  quarter  versus 90% in the
comparable  period of last year. The  AngioDynamics  products  industry  segment
includes  stent  products,  angiographic  and  fluid  management  products,  and
thrombolytic   products  used  in  the  interventional   medicine   marketplace.
AngioDynamics product sales, net of intersegment eliminations, increased 105% in
the quarter and  represented  20% of sales in the current  quarter versus 10% in
the comparable period of the prior year.

     Diagnostic  segment  results for both the current  quarter and  comparative
quarter  of last year were  adversely  affected  by  unabsorbed  overhead  costs
associated  with the relocation of a portion of the Company's  contrast  systems
manufacturing  operations.  These costs resulted during the planned construction
at the Company's Canadian manufacturing  facility. The effects of the relocation
will  continue to be felt through the third fiscal  quarter of the current year,
resulting in lower than normal  Canadian gross profits.  Diagnostic  results for
the current quarter were also adversely affected by a decline in sales,  coupled
with increased selling and marketing  expenses in the Company's contrast systems
business.

     AngioDynamics  segment  results for the  current  quarter  were  positively
affected by sales growth of 105%,  resulting  from  domestic  and  international
market penetration and the introduction of the AngioStentTM.  The AngioStent,  a
device used during coronary procedures as a treatment for  atherosclerosis,  was
introduced  in the third  quarter  of the prior  year in  certain  international
markets.  AngioDynamics  contributed  operating  profits of $419,000 to E-Z-EM's
consolidated  operations in the current  quarter,  an improvement of $868,000 as
compared to operating losses of $449,000 in the comparable  quarter of the prior
year.   Approximately   $200,000   of   this   improvement   is   due   to   the
commercialization,  in the second  quarter of the prior year,  of the  Company's
CO2JECTTM  system,  which delivers  carbon dioxide gas as a replacement for more
expensive iodinated contrast media.

     CONSOLIDATED RESULTS OF OPERATIONS

     For the quarter ended August 31, 1996, the Company reported net earnings of
$513,000, or $.05 per common share on both a primary and fully diluted basis, as
compared to net earnings of $569,000, or $.06 per common share on both a primary
and fully diluted basis, for the comparable period of last year.

                                      -11-
<PAGE>
     Earnings from continuing  operations for the current quarter were $513,000,
or $.05 per common share on both a primary and fully diluted basis,  as compared
to $740,000, or $.08 per common share on both a primary and fully diluted basis,
for the comparable period of last year.  Results from continuing  operations for
both the current  quarter and  comparative  quarter of last year were  adversely
impacted by  unabsorbed  overhead  costs  associated  with the  relocation  of a
portion of the Company's contrast systems manufacturing operations. Results from
continuing  operations for the current quarter were also adversely affected by a
decline in sales, coupled with increased selling and marketing expenses,  in the
Company's  contrast systems  business,  partially offset by AngioDynamics  sales
growth.

     Net  sales  for  the  quarter  ended  August  31,  1996  increased  6%,  or
$1,356,000, as compared to the quarter ended September 2, 1995. Net sales in the
current  quarter were  favorably  affected by increased  AngioDynamics  sales of
$2,358,000 and price  increases,  which  accounted for nearly 1% of sales in the
current  quarter.  The  AngioDynamics  sales  growth  was  due to  domestic  and
international  market  penetration and the  introduction of the AngioStent.  Net
sales in the  current  quarter  were  adversely  affected  by a  decline  in the
Company's  sales  of  contrast  systems.  Net  sales in  international  markets,
including  direct exports from the U.S.,  increased  15%, or $1,149,000,  in the
current quarter versus the comparable period of last year due to increased sales
of AngioDynamics products of $1,816,000,  partially offset by decreased sales of
non-contrast systems of $379,000 and contrast systems of $288,000.

     Gross profit  expressed  as a  percentage  of sales was 42% during both the
current quarter and the comparable quarter of the prior year. During the current
and prior year  quarter,  gross  profit was  negatively  impacted by  unabsorbed
overhead costs  approximating  $719,000 and $670,000,  respectively.  Such costs
were  associated  with the  relocation  of a portion of the  Company's  contrast
systems manufacturing operations.

     Selling and  administrative  ("S&A")  expenses were  $7,835,000  during the
quarter  ended  August 31,  1996  versus  $6,990,000  during the  quarter  ended
September 2, 1995. This increase of $845,000, or 12%, in the current quarter was
principally  due to increased  selling and  marketing  expenses in the Company's
contrast systems business of $384,000 and increased  AngioDynamics  S&A expenses
of $303,000.  Investment in new product  introductions and marketing initiatives
contributed  to the increased  selling and  marketing  expenses in both industry
segments.  The  Company  realized a gain on the sale of a facility  of  $143,000
during  the  quarter   ended   September   2,  1995  which  also   affected  the
quarter-to-quarter comparison.

     Research and development ("R&D") expenditures  increased 16% in the current
quarter to $1,523,000,  or 7% of sales, from $1,317,000,  or 6% of sales, in the
comparable quarter of the prior year due to increased contrast systems spending.
Of the R&D  expenditures  in the current  quarter,  approximately  39% relate to
contrast systems, 36% to AngioDynamics  projects, 4% to immunological  projects,
12% to other projects and 9% to general  regulatory  costs. R&D expenditures are
expected to continue at approximately current levels.

     Other income,  net of expenses,  increased  $156,000 in the current quarter
versus the  comparable  period of last year due primarily to increased  interest
income of $154,000,  resulting from the investment of proceeds  arising from the
sale of Surgical Dynamics in the second quarter of the prior year.

                                      -12-
<PAGE>
     The Company's effective tax rate of 28% during the quarter ended August 31,
1996  differed  from the  Federal  statutory  tax rate of 34% due  primarily  to
earnings of the Puerto Rican subsidiary, which are subject to favorable U.S. tax
treatment, tax-exempt interest income, and the utilization of net operating loss
carryforwards  in a certain  jurisdiction.  For the quarter  ended  September 2,
1995,  the  Company's  effective  tax  rate of 15%  differed  from  the  Federal
statutory  tax  rate  of 35% due  primarily  to  earnings  of the  Puerto  Rican
subsidiary, which are subject to favorable U.S. tax treatment.

LIQUIDITY AND CAPITAL RESOURCES

     During the quarter ended August 31, 1996,  increased  inventory  levels and
capital  expenditures  were funded primarily by cash reserves.  In the past, the
Company's  policy  has  been  to fund  capital  requirements  without  incurring
significant  debt.  At August 31,  1996,  debt was  $2,289,000  as  compared  to
$1,927,000 at June 1, 1996. The Company has available  $4,731,000 under two bank
lines of credit of which $948,000 was outstanding at August 31, 1996.

     The Company's current policy is to issue stock dividends.  During the third
quarter of fiscals 1994, 1995 and 1996, the Company issued 3% stock dividends.

     Presently, the Company is continuing to look for both new and complementary
lines of business for expansion in order to ensure its continued growth.

     At August 31, 1996,  approximately  67% of the Company's  assets consist of
inventories, debt and equity securities,  accounts receivable, and cash and cash
equivalents. Inventories have increased at a greater rate than sales as a result
of broadened  product lines, and safety stock during the relocation of a portion
of the Company's contrast systems manufacturing operations. The current ratio is
5.05 to 1, with net  working  capital  of  $54,172,000  at August 31,  1996,  as
compared  to the  current  ratio  of 5.15 to 1,  with  net  working  capital  of
$53,508,000 at June 1, 1996.

     This Form 10-Q  contains  certain  forward-looking  statements  within  the
meaning  of  Section  27A of  the  Securities  Act  of  1933,  as  amended  (the
"Securities  Act"),  and Section 21E of the Securities  Exchange Act of 1934, as
amended  (the  "Exchange  Act"),  which are  intended  to be covered by the safe
harbors  created  thereby.  Investors  are cautioned  that all forward-  looking
statements  involve risks and uncertainty,  including  without  limitation,  the
ability of the  Company  to  develop  its  products,  as well as general  market
conditions,  competition  and pricing.  Although the Company  believes  that the
assumptions  underlying  the  forward-looking  statements  contained  herein are
reasonable, any of the assumptions could be inaccurate, and therefore, there can
be no assurance that the  forward-looking  statements included in this Form 10-Q
will prove to be accurate. In light of the significant uncertainties inherent in
the   forward-looking   statements   included  herein,  the  inclusion  of  such
information  should not be  regarded as a  representation  by the Company or any
other person that the objectives and plans of the Company will be achieved.

                                      -13-
<PAGE>
                          E-Z-EM, Inc. and Subsidiaries

                           Part II: Other Information


ITEM 5.  OTHER INFORMATION

     During September 1996, the Company  announced that  AngioDynamics,  Inc., a
wholly-owned  subsidiary,  will offer up to 20% of its equity to the public. The
offering  is  expected  to  occur in early  1997  and is  expected  to be a firm
commitment  underwriting.  The  offering  will  be  made  only  by  means  of  a
prospectus.


ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K                               PAGE

     (a)  Exhibit 27 - Financial data schedule                           15

     (b)  No  reports on Form 8-K were filed for the quarter
          ended August 31, 1996.


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.




                                          E-Z-EM, Inc.
                                          ------------
                                          (Registrant)




Date   October 11, 1996                   /s/ Daniel R. Martin
       ------------------                -----------------------------------
                                          Daniel R. Martin, President, Chief
                                          Executive Officer and Director




Date   October 11, 1996                   /s/ Dennis J. Curtin
       ------------------                -----------------------------------
                                          Dennis J. Curtin, Vice President-
                                          Chief Financial Officer





                                      -14-